Article
Post-Progression Survival after EGFR-TKI for Advanced Non-Small Cell Lung Cancer Harboring EGFR Mutations.
PloS one - 1 Jan 2015
Kogure Yoshihito, Saka Hideo, Oki Masahide, Saito Toshiki I, Ahmed Shimaa Nour Moursi, Kitagawa Chiyoe, Imaizumi Kazuyoshi
Abstract excerpt
BACKGROUND: Non-small cell lung cancer (NSCLC) patients that harbor epidermal growth factor receptor (EGFR) mutations benefit from receiving an EGFR-tyrosine kinase inhibitor (TKI); however, post-progression survival (PPS) after EGFR-TKI treatment has not been sufficiently studied. METHODS: We retrospectively reviewed the clinical data from stage IV or recurrent NSCLC patients who harbored EGFR mutations and who...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.